Annals of Hematology

, Volume 92, Issue 8, pp 1041–1048 | Cite as

DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center

  • Jan-Henrik Mikesch
  • Mareike Kuhlmann
  • Angela Demant
  • Utz Krug
  • Gabriela B. Thoennissen
  • Eva Schmidt
  • Torsten Kessler
  • Christoph Schliemann
  • Michele Pohlen
  • Michael Mohr
  • Georg Evers
  • Gabriele Köhler
  • Johannes Wessling
  • Rolf Mesters
  • Carsten Müller-Tidow
  • Wolfgang E. Berdel
  • Nils H. Thoennissen
Original Article

Abstract

High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) is considered standard in the treatment of patients with relapsed or refractory aggressive peripheral T cell lymphoma (PTCL). However, the optimal salvage regimen before ASCT has not yet been established. We retrospectively analyzed 31 patients with relapsed or refractory aggressive PTCL after anthracycline-based first-line chemotherapy who received either DexaBEAM (dexamethasone, carmustine, etoposide, cytarabine, and melphalan; n = 16) or ICE (ifosfamide, carboplatin, and etoposide; n = 15) regimen as first salvage chemotherapy followed by HDT/ASCT. The overall response rate (OR) was significantly higher for patients treated with DexaBEAM (69 %; 95 % confidence interval 46.0–91.5 %) as compared to the ICE group (20 %; 95 % confidence interval −0.2–40.2 %; P = 0.01), with higher complete response (CR; 38 %; 95 % confidence interval 13.8–61.2 %; vs. 7 %; 95 % confidence interval −6.0–19.6 %) as well as partial response (PR; 31 vs. 13 %) rate. Changing regimen due to failure of first salvage therapy, 12 patients initially receiving ICE still achieved an OR of 58 % (33 % CR, 25 % PR) with DexaBEAM as second salvage therapy, whereas in three patients receiving ICE after DexaBEAM failure, only one achieved an OR (1 PR). Median progression-free survival was significantly higher in the DexaBEAM group (6.4 vs. 2 months; P = 0.01). Major adverse event in both groups was myelosuppression with higher but tolerable treatment-related toxicity for patients in the DexaBEAM group. For all patients proceeding to HDT/ASCT, a 3-year overall survival was 50 %. Together, considering the limitations of the retrospective design of the evaluation and the small sample size, our data suggest that DexaBEAM salvage chemotherapy is superior to ICE for patients with relapsed or refractory aggressive PTCL for remission induction prior to autologous transplantation, with higher but manageable treatment-related toxicity.

Keywords

DexaBEAM ICE Peripheral T cell lymphoma Salvage therapy 

Notes

Conflict of Interest

The authors have declared no potential conflicts of interest.

References

  1. 1.
    Foss FM, Zinzani PL, Vose JM, Gascyone RD, Rosen ST, Tobinai K (2011) Peripheral T-cell lymphoma. Blood 117:6756–6767PubMedCrossRefGoogle Scholar
  2. 2.
    Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380:848–857PubMedCrossRefGoogle Scholar
  3. 3.
    Vose J, Armitage J, Weisenburger D (2008) International T-Cell Lymphoma Project. International peripheral T-Cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130PubMedCrossRefGoogle Scholar
  4. 4.
    Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRefGoogle Scholar
  5. 5.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127PubMedCrossRefGoogle Scholar
  6. 6.
    Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International trial (MInT) Group (2008) Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9:435–444PubMedCrossRefGoogle Scholar
  7. 7.
    Armitage JO (2012) The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87:511–519PubMedCrossRefGoogle Scholar
  8. 8.
    Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ, Weisenburger DD, Armitage JO, Mounier N, Vose JM (2013) Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma (AITL): analysis of 243 cases from the International Peripheral T-cell Lymphoma Project. J Clin Oncol 31:240–246PubMedCrossRefGoogle Scholar
  9. 9.
    Ferreri AJ, Govi S, Pileri SA, Savage KJ (2012) Anaplastic large cell lymphoma, ALK positive. Crit Rev Oncol Hematol 83:293–302PubMedCrossRefGoogle Scholar
  10. 10.
    Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD, International Peripheral T-Cell Lymphoma Project (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International T-Cell Lymphoma Project. Blood 111:5496–5504PubMedCrossRefGoogle Scholar
  11. 11.
    Greer JP (2006) Therapy of peripheral T/NK neoplasm. Hematol Am Soc Hematol Educ Program 2006:331–337CrossRefGoogle Scholar
  12. 12.
    Philip T, Guglielmini C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545PubMedCrossRefGoogle Scholar
  13. 13.
    Gutiérrez A, Caballero MD, Pérez-Manga G, Rodriguez J (2008) Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant 42:773–781PubMedCrossRefGoogle Scholar
  14. 14.
    Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N, Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:218–224PubMedGoogle Scholar
  15. 15.
    Hosing C, Champlin RE (2011) Stem-cell transplantation in T-cell non-Hodgkin lymphomas. Ann Oncol 22:1471–1477PubMedCrossRefGoogle Scholar
  16. 16.
    Schetelig J, Fetscher S, Reichle A, Berdel WE, Beguin Y, Brunet S, Caballero D, Majolino I, Hagberg H, Johnsen HE, Kimby E, Montserrat E, Stewart D, Copplestone A, Rösler W, Pavel J, Kingreen D, Siegert W (2003) Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88:1272–1278PubMedGoogle Scholar
  17. 17.
    Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Jang S, Park CJ, Chi HS, Huh J, Suh C (2007) High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Haematol 86:435–442CrossRefGoogle Scholar
  18. 18.
    Rodríguez J, Caballero MD, Gutiérrez A, Marin J, Lahuerta JJ, Sureda A, Carreras E, Leon A, Arranz R, Fernandez de Sevilla A, Zuazu J, Garcia-Larana J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde (2003) High dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14:1768–1775PubMedCrossRefGoogle Scholar
  19. 19.
    Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large cell lymphoma in the rituximab era. J Clin Oncol 28:4184–4190PubMedCrossRefGoogle Scholar
  20. 20.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
  21. 21.
    Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 92:3562–3568PubMedGoogle Scholar
  22. 22.
    Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989–1996PubMedCrossRefGoogle Scholar
  23. 23.
    Atta J, Chouw KU, Weidmann E, Mitrou PS, Hoelzer D (2007) Martin H (2007) DexaBEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma 48:349–356PubMedCrossRefGoogle Scholar
  24. 24.
    Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol Suppl 1:i5–i10CrossRefGoogle Scholar
  25. 25.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippenstein D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253PubMedGoogle Scholar
  26. 26.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRefGoogle Scholar
  27. 27.
    Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG (2008) Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 14:741–747PubMedCrossRefGoogle Scholar
  28. 28.
    D’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Ostenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012) Up-front autologous stem cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30:3093–3099PubMedCrossRefGoogle Scholar
  29. 29.
    Josting A, Sienawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A (2005) High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a multicenter phase II study. Ann Oncol 16:1359–1365PubMedCrossRefGoogle Scholar
  30. 30.
    Kim KH, Joo YD, Sohn CH, Shin HJ, Chung JS, Cho GJ, Shin SH, Kim YS, Lee WS (2009) Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin’s lymphoma. Korean J Intern Med 24:37–42PubMedCrossRefGoogle Scholar
  31. 31.
    Park BB, Kim WS, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K (2005) IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. Leuk Lymphoma 46:1743–1748PubMedCrossRefGoogle Scholar
  32. 32.
    Pro B, Advani RH, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab vedotin (SGN-35) in patients with relapsed of refractory systemic anaplastic large cell lymphoma: results of a phase II study. J Clin Oncol 30:2190–2196PubMedCrossRefGoogle Scholar
  33. 33.
    Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631–636PubMedCrossRefGoogle Scholar
  34. 34.
    Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920–2924PubMedCrossRefGoogle Scholar
  35. 35.
    Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316–2323PubMedCrossRefGoogle Scholar
  36. 36.
    Kim SJ, Kim K, Kim BS, Suh C, Huh J, Ko YH, Kim WS (2009) Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 20:390–392PubMedCrossRefGoogle Scholar
  37. 37.
    Prichard M, Harris T, Williams ME, Densmore JJ (2009) Treatment strategies for relapsed and refractory aggressive non-Hodgkin’s lymphoma. Expert Opin Pharmacother 10:983–995PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Jan-Henrik Mikesch
    • 1
  • Mareike Kuhlmann
    • 1
  • Angela Demant
    • 1
  • Utz Krug
    • 1
  • Gabriela B. Thoennissen
    • 1
  • Eva Schmidt
    • 1
  • Torsten Kessler
    • 1
  • Christoph Schliemann
    • 1
  • Michele Pohlen
    • 1
  • Michael Mohr
    • 1
  • Georg Evers
    • 1
  • Gabriele Köhler
    • 2
  • Johannes Wessling
    • 3
  • Rolf Mesters
    • 1
  • Carsten Müller-Tidow
    • 1
  • Wolfgang E. Berdel
    • 1
  • Nils H. Thoennissen
    • 1
  1. 1.Department of Medicine, Hematology and OncologyUniversity Hospital of MuensterMuensterGermany
  2. 2.Department of PathologyUniversity Hospital of MuensterMuensterGermany
  3. 3.Department of RadiologyUniversity Hospital of MuensterMuensterGermany

Personalised recommendations